CM
Claire Mazumdar
Chief Executive OfficerDirector

Claire Mazumdar insider trades: Bicara Therapeutics (BCAX) stock sales

Chief Executive Officer, Bicara Therapeutics Last trade Aug 10, 2026 12 Form 4 filings
$2.1M
Sold, last 12 months
6 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2025
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Claire reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 10, 2026BCAX↓ Sell$280K
Jul 10, 2026BCAX↓ Sell$284K
May 18, 2026BCAX↓ Sell$301K
Mar 20, 2026BCAX↓ Sell$282K
Mar 6, 2026BCAX↓ Sell$154K
Nov 24, 2025BCAX↓ Sell$776K
Oct 16, 2025BCAX↓ Sell$454K
Oct 15, 2025BCAX↓ Sell$467K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other BCAX insiders

Open-market trades in the last 12 months

About Claire Mazumdar's insider trades

Claire Mazumdar is Chief Executive Officer at Bicara Therapeutics (BCAX). Since Oct 15, 2025, Claire has reported no open-market purchases and 8 sales worth $3.0M on SEC Form 4. In the last 12 months: 6 sales ($2.1M).

Their filings also include option exercises (9 filings), grants and awards (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCAX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.